Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 2
2010 2
2011 1
2013 2
2014 2
2015 6
2016 2
2017 1
2019 2
2020 3
2021 3
2022 1
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Moving Pharmacogenetics Into Practice: It's All About the Evidence!
Luzum JA, Petry N, Taylor AK, Van Driest SL, Dunnenberger HM, Cavallari LH. Luzum JA, et al. Clin Pharmacol Ther. 2021 Sep;110(3):649-661. doi: 10.1002/cpt.2327. Epub 2021 Jul 7. Clin Pharmacol Ther. 2021. PMID: 34101169 Free PMC article. Review.
Therefore, the purpose of this review is to summarize different perspectives on the evidence required for the clinical implementation of pharmacogenetics. ...However, clinicians and practice guidelines from medical societies often rely on RCT da …
Therefore, the purpose of this review is to summarize different perspectives on the evidence required for the clinical impleme …
Clinician Perspectives on Using Pharmacogenomics in Clinical Practice.
Unertl KM, Jaffa H, Field JR, Price L, Peterson JF. Unertl KM, et al. Per Med. 2015;12(4):339-347. doi: 10.2217/pme.15.10. Per Med. 2015. PMID: 26635887 Free PMC article.
AIM: To describe the knowledge and attitudes of clinicians participating in a large pharmacogenomics implementation program. ...CONCLUSIONS: Clinicians identified their own knowledge deficits, workflow integration, and longitudinal responsibility as challenge …
AIM: To describe the knowledge and attitudes of clinicians participating in a large pharmacogenomics implementation program. . …
Pharmacogenetic Aspects of Drug Metabolizing Enzymes and Transporters in Pediatric Medicine: Study Progress, Clinical Practice and Future Perspectives.
Zhao J, Bian J, Zhao Y, Li Y, Liu B, Hao X, He S, Huang L. Zhao J, et al. Paediatr Drugs. 2023 May;25(3):301-319. doi: 10.1007/s40272-023-00560-3. Epub 2023 Jan 27. Paediatr Drugs. 2023. PMID: 36707496 Review.
We also further discuss the research status of the gene-guided dosing regimens and clinical implementation of pediatric pharmacogenetics. More and more drug-gene interactions are demonstrated to have clinical validity for children, and pharmacogenomics …
We also further discuss the research status of the gene-guided dosing regimens and clinical implementation of pediatric pharmacoge …
Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian.
Wu AH, Babic N, Yeo KJ. Wu AH, et al. Per Med. 2009 May;6(3):315-327. doi: 10.2217/pme.09.1. Per Med. 2009. PMID: 29783510
Despite widespread interest in personalized medicine, the implementation of clinical pharmacogenomics has been slow. The major issue for clinicians is the lack of evidence that pharmacogenomic testing improves clinical outcomes and that testing …
Despite widespread interest in personalized medicine, the implementation of clinical pharmacogenomics has been slow. The major …
Past, present and future perspectives of therapeutic drug monitoring in India.
Advani M, Seetharaman R, Pawar S, Mali S, Lokhande J. Advani M, et al. Int J Clin Pract. 2021 Aug;75(8):e14189. doi: 10.1111/ijcp.14189. Epub 2021 Apr 20. Int J Clin Pract. 2021. PMID: 33774900 Review.
Therapeutic drug monitoring (TDM) is the clinical practice of performing drug assays and interpreting results to maintain constant therapeutic concentrations in patients' bloodstream. ...However, the newer indications such as antimicrobial resistance, tuberculosis a …
Therapeutic drug monitoring (TDM) is the clinical practice of performing drug assays and interpreting results to maintain cons …
Integrating Pharmacogenomics into Clinical Practice: Promise vs Reality.
St Sauver JL, Bielinski SJ, Olson JE, Bell EJ, Mc Gree ME, Jacobson DJ, McCormick JB, Caraballo PJ, Takahashi PY, Roger VL, Rohrer Vitek CR. St Sauver JL, et al. Am J Med. 2016 Oct;129(10):1093-1099.e1. doi: 10.1016/j.amjmed.2016.04.009. Epub 2016 May 5. Am J Med. 2016. PMID: 27155109 Free PMC article.
BACKGROUND: Limited information is available regarding primary care clinicians' response to pharmacogenomic clinical decision support (PGx-CDS) alerts integrated in the electronic health record. METHODS: In February 2015, 159 clinicians in the Mayo Cli …
BACKGROUND: Limited information is available regarding primary care clinicians' response to pharmacogenomic clinical de …
The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?
Dias MM, Sorich MJ, Rowland A, Wiese MD, McKinnon RA. Dias MM, et al. Pharm Res. 2017 Aug;34(8):1544-1550. doi: 10.1007/s11095-017-2128-0. Epub 2017 Feb 24. Pharm Res. 2017. PMID: 28236061 Review.
However, despite the potential benefits, pharmacogenetic testing is mostly confined to specialised medical areas, laboratories and centres. Widespread integration into routine clinical practice has been limited by a complex set of issues including regulatory and rei …
However, despite the potential benefits, pharmacogenetic testing is mostly confined to specialised medical areas, laboratories and centres. …
Clinical Utilization of Pharmacogenetics in Psychiatry - Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry.
Brown L, Eum S, Haga SB, Strawn JR, Zierhut H. Brown L, et al. Pharmacopsychiatry. 2020 Jul;53(4):162-173. doi: 10.1055/a-0975-9595. Epub 2019 Sep 11. Pharmacopsychiatry. 2020. PMID: 31509860 Review.
INTRODUCTION: The use of pharmacogenomic (PGx) testing to guide decisions and improve patient outcomes has increased in recent years. ...METHODS: This is a narrative review of utilization of PGx testing in psychiatry from stakeholders including, pharmacists, genetic counse …
INTRODUCTION: The use of pharmacogenomic (PGx) testing to guide decisions and improve patient outcomes has increased in recent years. …
Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.
Pushpam D, Bakhshi S. Pushpam D, et al. Daru. 2020 Jun;28(1):371-385. doi: 10.1007/s40199-019-00321-z. Epub 2020 Jan 3. Daru. 2020. PMID: 31900888 Free PMC article. Review.
OBJECTIVE: In this review, we have summarized the pharmacokinetics, pharmacodynamics and adverse effects of imatinib, dasatinib, nilotinib, bosutinib, ponatinib and radotinib with focus on pharmacogenomic studies with clinical end points. We have discussed the key p …
OBJECTIVE: In this review, we have summarized the pharmacokinetics, pharmacodynamics and adverse effects of imatinib, dasatinib, nilotinib, …
Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy.
Hertz DL. Hertz DL. Pharmacogenomics J. 2019 Oct;19(5):411-416. doi: 10.1038/s41397-019-0093-1. Epub 2019 Aug 9. Pharmacogenomics J. 2019. PMID: 31395959 Free PMC article. Review.
Clinician-rated toxicity data has been systematically collected within oncology clinical research using the National Cancer Institute's CTCAE scale, providing estimates of the occurrence and severity of toxicity from cancer treatment. CTCAE is being supplemen …
Clinician-rated toxicity data has been systematically collected within oncology clinical research using the National Cancer In …
28 results